Updated hourlyHourly refreshWed, Jul 15, 2026
Press Release Database
Recent press releases, indexed by topic.
Healthcare
(PR-inside.com) MIAMI, FL / ACCESS Newswire / July 15, 2026 / Aimwell Partners Inc. (OTCID:AIMN), parent company of AimwellBio, today confirmed it is engaged in advanced discussions with an exclusive, referral-based life sciences capital markets network that connects biotechnology companies with institutional investors, banking relationships, strategic advisors, and other participants across the biotech investment ecosystem. The introduction originated through Christopher A. Jones, PhD, FRSM, Strategic Advisor to AimwellBio and one of the founding credentialed contributors to the company's Federated Health Intelligence Network. The company expects negotiations to conclude next week, at which time the counterparty and the scope of the relationship are anticipated ..
Jul 15 · 12:31·PR-Inside
Finance · Healthcare
(PR-inside.com) CEO Explains How Broad Patent Protection, Combined with First-Ever FDA IDE Approval, Positions enVVe® to Own a Multi-Billion-Dollar Venous Disease Market Watch the "What This Means" video here IRVINE, CA / ACCESS Newswire / July 15, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that Robert Berman, Chief Executive Officer of enVVeno Medical participated in a Virtual Investor "What This Means" segment. As part of the segment, Mr. Berman discussed the Company's recent news announcing the issuance of the first U.S. Patent covering the company's enVVe system, further expanding its intellectual property portfolio and laying the groundwork to ..
Jul 15 · 12:31·PR-Inside
Finance · Healthcare
Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson
Jul 15 · 12:30·GlobeNewswire
Healthcare
As Southern Utah temperatures climb, St. George foot and ankle clinic highlights how extreme heat can affect foot and ankle health and ways to lower risk. The post Foot & Ankle Center Warns Southern Utah Residents of Overlooked Summer Heat Risks first appeared on
Jul 15 · 12:28·PRUnderground
Healthcare
(PR-inside.com) MALMÖ, SE / ACCESS Newswire / July 15, 2026 / Ascelia Pharma (STO:ACE), a biotech company focused on improving the lives of people with rare cancer conditions, today announces that CFO Anton Hansson will be leaving the Company. In connection with this change and cost reduction initiatives, Ascelia Pharma is reducing its cost base while focusing on the path forward for Orviglance®. The changes support alignment of resources with Ascelia Pharma's current priorities, including regulatory interactions with the U.S. Food and Drug Administration ("FDA") and bringing Orviglance to patients. "Our focus is on the upcoming Type A meeting with the FDA where ..
Jul 15 · 12:05·PR-Inside
SaaS · Healthcare
(PR-inside.com) WOODSTOCK, GA / ACCESS Newswire / July 15, 2026 / SlicedHealth has launched GROW, an operational platform designed to give small and mid-sized hospitals the same clarity and control over contracts, credentialing, and compliance that has traditionally only been available to much larger health systems. GROW connects agreements to the day to day activity they are supposed to govern, so a hospital can see not just what a contract says, but whether it is actually being honored in practice. For years, the advice to rural and community hospitals was simple. Protect your margin, control your costs, and keep the doors open. ..
Jul 15 · 12:01·PR-Inside
Finance · Healthcare
(PR-inside.com) Completed Independent Study Strongly Supports Favorable Payor Receptivity to Pivot's Differentiated Design and Simplified User Experience, and provides further validation of significant progress towards goal of achieving broad market access for Pivot SAN DIEGO, CA / ACCESS Newswire / July 15, 2026 / Modular Medical, Inc. ("Modular Medical" or "the Company") (NASDAQ:MODD), a commercial-stage medical device company that is commercializing the next generation of insulin delivery technology, today released findings from an independent market research study demonstrating positive receptivity to its FDA-cleared Pivot™ tubeless patch pump due to its differentiated design, streamlined user experience, and potential for reimbursement through the pharmacy ..
Jul 15 · 12:00·PR-Inside
Finance · AI
CARACAS, VENEZUELA - July 15, 2026 ( NEWMEDIAWIRE ) - LataMed AI Corp. (OTC: LMEDD) (the “Company”) today announced that its previously announced 5-for-1 forward stock split has become effective at the opening of trading following publication of the corporate action on the FINRA Daily List dated July 14, 2026. In connection with the forward stock split, the Company's common stock will begin trading today under the temporary trading symbol LMEDD . The temporary "D" designation is a standard FINRA identifier used in connection with certain corporate actions and is expected to remain in place for approximately twenty (20) business days, after which the trading symbol is expected to revert to LMED . The forward stock split has also been implemented in conjunction with the Company's mandatory s
Jul 15 · 12:00·NewMediaWire
Healthcare
Completed Independent Study Strongly Supports Favorable Payor Receptivity to Pivot's Differentiated Design and Simplified User Experience, and provides further validation of significant progress towards goal of achieving broad market access for Pivot
Jul 15 · 12:00·Newswire.com
Healthcare
Company expands support for CMS' ACCESS Model and the Medicare GLP-1 Bridge, helping healthcare organizations operationalize technology-enabled, longitudinal care at scale AUSTIN, Texas, July 15, 2026 /PRNewswire-PRWeb/ -- Wheel, the leading clinical infrastructure company powering...
Jul 15 · 12:00·PRWeb
Healthcare
BEIJING, July 15, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that registrational phase III clinical study results of novel TYK2 (Tyrosine Kinase 2) inhibitor soficitinib (ICP-332) met the primary endpoint in patients with moderate-to-severe atopic dermatitis (AD).
Jul 15 · 11:54·GlobeNewswire
Finance · Healthcare
Independent CRO Successfully Reproduces ERNA-101 Combination Data in Larger Preclinical Study, Significantly Strengthening Confidence as Company Advances Toward IND
Jul 15 · 11:50·GlobeNewswire